公开(公告)号：US5324748A

公开(公告)日：1994-06-28

申请号：US956460

申请日：1992-10-02

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/23 ,  A61K38/21 ,  A61K45/06 ,  A61K31/015 ,  A61K31/07

CPC classification number: A61K38/21 ,  A61K31/20 ,  A61K31/23 ,  A61K45/06

Abstract: A composition of an effective amount of (a) .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid, optionally in association with linoleic and if desired other fat acids, said acids being used if desired as physiologically functional derivatives thereof, in conjunction with (b) an effective amount of one or more of natural or synthetic carotenoids or retinoids having, or giving rise in the body to compounds having, Vitamin A activity when used in therapy of a condition in which enhancement of 1-series PG production, or more broadly influence of the 1-series/2-series PG balance in the body in favor of 1-series PGs is required.

Abstract translation: 有效量的（a）γ-亚麻酸和/或二 - γ-亚麻酸的组合物，任选地与亚油酸和任何其它脂肪酸一起使用，如果需要，所述酸作为其生理功能衍生物，结合使用 与（b）有效量的一种或多种天然或合成类胡萝卜素或类视黄醇，当用于治疗1系PG生产增强的病症时，具有或引起体内具有维生素A活性的化合物， 或更广泛地影响1系列/ 2系PG平衡在体内有利于1系列PGs。

公开(公告)号：US5178873A

公开(公告)日：1993-01-12

申请号：US704603

申请日：1991-05-23

Applicant: David F. Horrobin ,  Michael J. Finnen

Inventor： David F. Horrobin ,  Michael J. Finnen

IPC: A61K31/20 ,  A61K31/202 ,  A61P29/00 ,  A61P43/00

CPC classification number: A61K31/20 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/861 ,  Y10S514/886 ,  Y10S514/887

Abstract: A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is administered alone or in a pharmaceutically acceptable diluent or carrier.

公开(公告)号：US5120760A

公开(公告)日：1992-06-09

申请号：US591604

申请日：1990-09-25

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/202 ,  A61K31/355 ,  A61P3/06 ,  A61P17/00 ,  A61P25/00 ,  A61P25/18 ,  A61P29/00 ,  A61P37/08

CPC classification number: A61K31/20 ,  A61K31/355

Abstract: Method of, and preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher n-6 series acides with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10 mg and 50 g of each acid.

公开(公告)号：US4997657A

公开(公告)日：1991-03-05

申请号：US321204

申请日：1989-03-09

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61F13/00 ,  A61K8/30 ,  A61K8/36 ,  A61K8/67 ,  A61K31/20 ,  A61K31/202 ,  A61L15/42 ,  A61P3/06 ,  A61Q19/00 ,  C07C57/12

CPC classification number: A61K8/361 ,  A61K31/20 ,  A61K8/67 ,  A61Q19/00 ,  A61K2800/92

Abstract: A composition, particularly an oral composition, for improving the smoothness of the skin, wherein GLA or DGLA or both as such or in the form of physiologically acceptable and equivalent derivatives are brought into administrable form with a carrier or diluent.

公开(公告)号：US4970076A

公开(公告)日：1990-11-13

申请号：US280410

申请日：1988-12-06

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K38/00 ,  A61K9/64 ,  A61K31/20 ,  A61K38/13 ,  A61P3/08 ,  A61P17/00 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00

CPC classification number: A61K38/13 ,  Y10S514/885 ,  Y10S514/922

Abstract: Composition of a cyclosporin and GLA and DGLA or derivative thereof convertible in the body thereto alone or in a pharmaceutical diluent or carrier.

公开(公告)号：US4931468A

公开(公告)日：1990-06-05

申请号：US642699

申请日：1984-08-21

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A23L1/29 ,  A23L1/30 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  A61P13/02 ,  A61P15/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00

CPC classification number: A61K38/21 ,  A61K31/20 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K45/06

Abstract: Use of .gamma.-linolenic acid and related materials with (i) zinc, .beta.-lactam antibiotics or other materials enhancing physiological l-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of malignant tumors susceptible to treatment with gamma-linolenic acid or dihomo-gamma-linolenic acid.

公开(公告)号：US4898885A

公开(公告)日：1990-02-06

申请号：US232515

申请日：1988-08-15

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/202 ,  A61K36/18 ,  A61P13/02 ,  A61P15/00 ,  C07C57/12

CPC classification number: A61K31/20

Abstract: A method of treatment of benign prostatic hypertrophy wherein .gamma.-linolenic acid or dihomo-.gamma.-linolenic acid or both, as such or in the form of an acceptable and physiologically equivalent derivatives, are administered to a person suffering from the same.

Abstract translation: 一种治疗良性前列腺肥大的方法，其中将γ-亚麻酸或二氢-γ-亚麻酸或两者本身或以可接受的和生理学上相似的衍生物的形式给予给患者。

公开(公告)号：US4888326A

公开(公告)日：1989-12-19

申请号：US168603

申请日：1988-03-04

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/35 ,  A61K31/37 ,  A61K31/70 ,  A61K36/00 ,  A61P29/00 ,  A61P37/04

CPC classification number: A61K31/70

Abstract: A pharmaceutical composition comprises one or more essential fatty acids, for example, .gamma.-linolenic acid or dihomo-.gamma.-linolenic acid, in conjunction with rutin, troxerutin or other bioflavonoid. The composition is useful in the treatment of inflammation or defective T-lymphocyte function.

Abstract translation: 药物组合物包含一种或多种必需脂肪酸，例如γ-亚麻酸或二高-γ-亚麻酸，与芦丁，troxerutin或其它生物类黄酮结合。 该组合物可用于治疗炎症或有缺陷的T淋巴细胞功能。

公开(公告)号：US4810497A

公开(公告)日：1989-03-07

申请号：US147208

申请日：1988-01-22

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K33/18 ,  A61K31/19 ,  A61K31/195 ,  A61K31/20 ,  A61K31/22 ,  A61K31/60 ,  A61K33/00 ,  A61K33/14 ,  A61P25/28 ,  A61K31/61 ,  A61K31/615 ,  A61K33/04

CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K33/00

Abstract: Presenile and senile dementia, in particular Alzheimer's disease, can be combated or alleviated by administration of an effective amount of a physiologically acceptable lithium compound and an essential fatty acid or a physiologically acceptable salt thereof.

公开(公告)号：US4806569A

公开(公告)日：1989-02-21

申请号：US45545

申请日：1987-05-04

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A23D9/00 ,  A23L1/30 ,  A23L1/325 ,  A23L1/48 ,  A61K31/16 ,  A61K31/20 ,  A61K31/22 ,  A61K31/23 ,  A61K31/557 ,  A61K35/56 ,  A61K35/60 ,  A61K36/00 ,  A61K36/185 ,  A61K38/00 ,  A61P3/08 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/30 ,  A61P27/16 ,  A61P35/00 ,  A61P37/08

CPC classification number: A61K35/60 ,  A23D9/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/557 ,  A61K36/185 ,  Y10S514/861 ,  Y10S514/866

Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3), 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto along or in an acceptable pharmaceutical carrier or diluent.